Loading...
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Wilkins, A Mossop, H Syndikus, I Khoo, V Bloomfield, D Parker, C Logue, John P Scrase, C Patterson, H Birtle, A
Wilkins, A
Mossop, H
Syndikus, I
Khoo, V
Bloomfield, D
Parker, C
Logue, John P
Scrase, C
Patterson, H
Birtle, A
Citations
Altmetric:
Abstract
Patient-reported outcomes (PROs) might detect more toxic effects of radiotherapy than do clinician-reported outcomes. We did a quality of life (QoL) substudy to assess PROs up to 24 months after conventionally fractionated or hypofractionated radiotherapy in the Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer (CHHiP) trial.
Affiliation
Description
Date
2015-10-27
Publisher
Collections
Keywords
Type
Article
Citation
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. 2015: Lancet Oncol, 16(16):1605-16